Novo Nordisk Investing $73M in Clayton, North Carolina, Facility
"The investment to expand our Clayton facility is another example of our commitment to improving diabetes treatment options in the U.S. by ensuring patients have access to the latest advances in treatment," said Jerzy Gruhn, president of Novo Nordisk Inc. "Insulin delivery devices give people with diabetes a convenient way to manage their health and engage in a productive lifestyle. As patients in the U.S. continue to move from administering insulin with a conventional vial and syringe to using a pen device, Novo Nordisk will be prepared to meet growing market demand."
The facility produces Novo Nordisk products including the Levemir FlexPen. The expansion will add two final assembly lines, two packing lines, along with refurbishing the building.
Cost and productivity factors, including state and local incentives, helped Novo Nordisk choose Clayton. The company has been approved for Job Development Investment Grant funds, as well as a $400,000 One North Carolina Fund grant.
Where to Invest in the Booming Aerospace Manufacturing Industry
2019 Auto/Aero Site Guide
A Site Selector’s Checklist for Locating in the U.S.
Location USA 2019
Front Line: Manufacturers Look to Nontraditional Locations
A Changing Food Manufacturing Industry
2017 Food Processing
The 3 Cs of Successful Site Selection: Company, Culture, and Community
2019 Gold & Silver Shovel Awards: Recipients Garnered Large Job-Creating and Investment Projects in Diverse Industries